AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease

AbbVie announced the European Commission approved SKYRIZI® (risankizumab, 600 mg intravenous [IV] induction and 360 mg subcutaneous [SC] maintenance therapy) as the first specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn’s disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy...READ MORE

Takeda Receives Prestigious Prix Galien Canada Innovative Product Award for TAKHZYRO® (lanadelumab)

Takeda Canada Inc. announce that TAKHZYRO® (lanadelumab), the first approved monoclonal antibody for the treatment of Hereditary Angioedema (HAE) has been named the 2022 winner of the prestigious Prix Galien Canada Innovative Product Award. The most prestigious award in the field of Canadian pharmaceutical research and innovation, Prix Galien Canada recognizes the efforts and achievements of pharmaceutical research and development. The annual award was presented at a gala ceremony in Toronto on November 15, 2022...READ MORE

Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)

Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody. Zanidatamab in combination with palbociclib and fulvestrant was well tolerated, with encouraging and durable antitumor activity in heavily pretreated patients with HER2-positive HR+ breast cancer. A poster with an updated and expanded data set will be presented at SABCS taking place in San Antonio, Texas and virtually on December 6-9, 2022...READ MORE

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

InMed Pharmaceuticals announced the closing of its previously announced private placement with two healthcare-focused institutional investors for the issuance and sale of 1,818,185 of its common shares at a purchase price of $3.30 per share (or pre-funded warrant in lieu thereof) priced at-the-market under Nasdaq rules. In addition, the Company has issued to the investors in the offering unregistered preferred investment options to purchase up to an aggregate of 3,272,733 common shares...READ MORE

NervGen Pharma Announces Composition of Matter Patent for NVG-291 Granted by the US Patent And Trade Office

NervGen Pharma Corp. announced that the US Patent and Trade Office (USPTO) has issued US Patent No. 11,497,812 B2 Compositions and Methods for Inhibiting the Activity of LAR Family Phosphatases to Case Western Reserve University. NervGen has an exclusive worldwide license to this patent and related proprietary technology which forms the technological foundation of its NVG-291 drug development program...READ MORE

Canadian Migraine Sufferers Have New Treatment Option – Health Canada Approves UBRELVY® (ubrogepant tablet)

AbbVie announced that Health Canada has approved UBRELVY® (ubrogepant tablet) for the acute treatment of migraine, with or without aura, in adults. UBRELVY® is the first orally-administered calcitonin gene-related peptide receptor antagonist for the treatment of migraine attacks once they start. An estimated 2.7 million Canadians have been diagnosed with migraine, which is estimated to underrepresent today’s migraine prevalence. Migraine is a complex neurological disease with recurrent attacks that lasts 4-72 hours. It is one of the leading causes of disability in the world...READ MORE

Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement

PharmAla Biotech Holdings Inc., a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA, and Mindset Pharma Inc., a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that they have entered into an exclusive sales agreement. Under the sales agreement, PharmAla will be the exclusive global reseller of Mindset’s cGMP psilocybin to appropriately licensed clinical researchers...READ MORE

Health Research Foundation Announces Recipient of its Medal of Honour

The Health Research Foundation of Innovative Medicines Canada announce that Dr. Allison McGeer is the recipient of its distinguished Medal of Honour. Dr. McGeer is an esteemed medical microbiologist and infectious diseases specialist at Mount Sinai Hospital, and Professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto...READ MORE

Government of Canada Announces Major Investments to Support Scientists, Researchers and Students

Government of Canada announced more than $1 billion in funding to support scientists, researchers and students. This investment, made through a number of funding programs, will support researchers across Canada in different fields, disciplines and stages of their careers. From upgrading research facilities to maintaining modern equipment, to supporting students and the establishment and renewal of Canada Research Chairs, this funding will ensure Canadian research continues to lead the world and push the boundaries of knowledge, while also supporting the next generation of young Canadians...READ MORE

Research Assistant, Process Development

Acuitas Therapeutics is seeking a Research Assistant to work in the Process Development group reporting to the Director, Chemistry, Manufacturing and Controls (CMC). The Research Assistant will be responsible for design and execution of studies, including development and characterization of manufacturing processes for lipid nanoparticle systems, supporting the transfer of manufacturing processes to third-party sites (CMOs), managing and executing analyses, as well as interpreting and presenting results. The Research Assistant will perform research related to the development of RNA LNP formulations for in vivo and in vitro applications, characterization of biophysical attributes, contribute to the understanding of the biological mechanisms of action and to optimization of formulation processes at various scales.

LEARN MORE

Computational Scientist, Drug Design

Computational Scientist will focus on developing and applying AI/ML approaches to small molecule design to support Gandeeva’s drug discovery programs. This role involves both the development of innovative computational methods as well as the application/evaluation of established methods towards the invention of novel medicines. Candidate will develop new scientific workflows for the discovery of small-molecule drugs. Apply various cheminformatic and modeling techniques to accelerate the development of hits into clinical candidates while collaborating with CADD/medicinal chemistry teams. Stay up to date with advances in machine learning and molecular modeling relevant to drug discovery. Improve the efficiency and accuracy of existing modeling tools and scientific workflows.

LEARN MORE

Senior Director of Finance

We're looking for a CA/CPA to build our financial infrastructure from the ground up, lead day-to-day accounting activities and help build a highly effective accounting function to support rapid growth. Reporting to the CEO, the individual in this role will be accountable for all accounting-related functions including financial statements in accordance with IFRS. As a business partner to the senior leadership team, you will assist in developing annual budgeting and operating plan; periodically assess organizational performance against the annual budget and the company’s long-term strategy. Develop tools and systems to provide critical financial and operational information to the senior leadership and make actionable recommendations on both strategy and operations.

LEARN MORE

Maka Health is an integrated digital portal where you can upload your personal health data – as well as the health data of anyone you care for – into a secure, intelligent AI software that will identify possible health issues and suggest treatment recommendations, vetted by experts in the field.

Visit Website

WestPAR was created to help bridge the critical gap in how start-up, small and medium-sized Pharmaceutical, Biotech and Medical Device Companies engage with Private and Public Payers with respect to reimbursement. WestPAR is adept at building reimbursement strategies including CDR submissions, pCPA negotiations, private payer submissions and both provincial and private payer engagement. Our national capabilities are broadened through our strategic partners based in Ontario and Quebec.

Visit Website